The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics.

The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Abstract Text:

OBJECTIVE: Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor used for the treatment of dyslipidaemia, may be co-administered with antacids in clinical practice. This trial assessed the effect of simultaneous and separated administration of an antacid preparation containing aluminium hydroxide 220 mg/5 mL and magnesium hydroxide 195 mg/5 mL (co-magaldrox 195/220) on the pharmacokinetics of rosuvastatin. RESEARCH DESIGN AND METHODS: A randomised, open-label, three-way crossover trial was performed. Healthy male volunteers (n = 14) received a single dose of rosuvastatin 40 mg alone, rosuvastatin 40 mg plus 20 mL antacid suspension taken simultaneously, and rosuvastatin 40 mg plus 20 mL antacid suspension taken 2 h after rosuvastatin on three separate occasions with a washout of > or = 7 days between each. Main outcome measures: The primary parameters were area under the rosuvastatin plasma concentration-time curve from time zero to the last quantifiable concentration (AUC(0-t)) and maximum observed rosuvastatin plasma concentration (C(max)) in the absence and presence of antacid. RESULTS: When rosuvastatin and antacid were given simultaneously, the antacid reduced the rosuvastatin AUC(0-t) by 54% (90% confidence interval [CI] for the treatment 0.40-0.53) and C(max) by 50% (90% CI 0.41-0.60). When the antacid was given 2 h after rosuvastatin, the antacid reduced the rosuvastatin AUC(0-t) by 22% (90% CI 0.68-0.90) and the C(max) by 16% (90% CI 0.70-1.01). The effect of repeated antacid administration was not studied and it cannot be discounted that this may have resulted in a stronger interaction than that observed here. CONCLUSIONS: Simultaneous dosing with rosuvastatin and antacid resulted in a decrease in rosuvastatin systemic exposure of approximately 50%. This effect was mitigated when antacid was administered 2 h after rosuvastatin.

The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Current medical research and opinion

VOLUME: 24

Page Numbers: 1231-5

Journal Abbreviation:

ISSN: 1473-4877

DAY: 19

MONTH: 03

YEAR: 2008

The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 351014

The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics.

AFFILIATION: AstraZeneca, Alderley Park, Cheshire, UK. paul.martin@astrazeneca.com

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Med Res Opin

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics Related Publications

• A robust nonlinear identification algorithm using PRESS statistic and forward regression.
• Antiplatelet therapy to prevent thrombosis after hip fracture.
• Chemical constitution and anthelminthic activity of cyclic analogues of phenothiazine.
• Cull peas as a protein supplement for swine feeding.
• Fractional flow reserve of pedicled left and right internal thoracic arteries.
• Gallbladder disease in cystic fibrosis.
• High frequency chest compression effects heart rate variability.
• Influence of reproductive stage upon the fertility of gonadotrophin-treated female rabbits.
• Involving HIV-positive people in policy and service development: Recent experiences in England.
• Letter by Poullis and Warwick regarding article, "Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival".
• Management of anaemia in haemodialysis and peritoneal dialysis patients (Chapter 8).
• Mechanisms of mucous transport.
• New concepts in orthopaedic thromboprophylaxis.
• Quantitative observations on the olfactory system of the rabbit.
• Radioiodination of humic substances via azocoupling with 3-[125I] iodoaniline.
• Serum calcium, phosphate, parathyroid hormone, albumin, aluminium and cholesterol achievement on replacement therapy (Chapter 9).
• Soft X-ray Monochromators for Third-Generation Undulator Sources.
• The cat-scratch syndrome, many diseases or one disease?
• The comparison of three high-frequency chest compression devices.
• The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics.
• The kinetics of effect of neuromuscular blocking drugs.
• Thoracic duct opacification for CT scanning.
• Trends in energy and macronutrient intake, body weight, level of physical activity, and energy expenditure in relation to dietary validity in female students - 1988 to 2003.
• Tubal pregnancy four months after cauterisation of the vaginal vault: One year following a vaginal hysterectomy.
• Two models of high frequency chest compression therapy: interaction of jacket pressure and mouth airflow.
• Urinary incontinence in women.
• Venous thromboembolic disease after total hip and knee arthroplasty: current perspectives in a regulated environment.
• Waveforms of High-frequency Chest Compression Systems Change With Jacket, Body.
• Why do patients known to renal services still undergo urgent dialysis initiation? A cross-sectional survey.